undervalued?, page-32

CortinaBoy,

It's always you isn't it!

It all about the active ingredient (think about heparin, then Lovenox and then Arixtra) and the ability to cross the blood brain barrier.

Glypromate was the clinically advanced product then nnz2256 was discovered.

In fact I have followed neu for a very long time, but I was never a fan of glypromate, only nnz2256.

Mouse models of IGF-1 were never sexy like nnz2256. It's not only the impressive results, but the fact that retts and FragileX can be so closely replicated (perhaps perfectly) with the afflicted mouse. As you will know, it is not always so easy to create a realistic (or actual) afflicted mouse.

Just to prove a difference between IGF-1 and nnz2256, you mentioned "...although IGF-1 has a terrible safety profile..." well nnz2256 has a perfect record.

On a sub note it has been suggested that IGF-1 was actually successful in its trial but it was too hard to prove. No problems with the Retts trial on that front as the evidence is pretty easy to determine.

One other thing, you claim to have held but you hold no more, but yet you keep posting on here. That's fine, healthy debate and all that. But I think one needs to look within sometimes and just check what ones motivation is. One needs to be honest with ones self if they do this.
Sometimes the need to justify ones own opinion or actions can get too great and bias.

I'm not saying that this is the case with yourself, but as a biotech investment neu still offers the best risk/reward ratio of any biotech I know. I stated this at 1.3c and it is still the case now (then we didn't have the Retts and FragileX information or people like Richard Treagus on board).

It is not to late to jump back on board. Don't argue with me, just do what I say!!!!

ok, I know you won't, but I did tell you! Expect "I told you so" in a few months.

Cheers and best wishes.